```html

Jackson–Stiel Disease (Pseudomyxoma Peritonei)

Overview

Pseudomyxoma peritonei (PMP), historically called Jackson–Stiel disease, is a rare condition in which mucin‑producing tumour cells seed the peritoneal cavity, creating a build‑up of thick, gelatinous fluid (mucin). This “jelly‑belly” can progressively stretch the abdomen, compress organs, and cause life‑threatening complications if left untreated.

• Incidence: Approximately 1‑2 cases per million people per year worldwide.<sup>1</sup> Estimated 3,000‑4,000 new diagnoses in the United States annually.
• Age: Median age at diagnosis is 55 years; 70 % of patients are 45–70 years old.
• Sex: Slight female predominance (≈55 % female, 45 % male), largely because many cases arise from appendiceal tumours, which are more common in women.
• Geography: No strong regional patterns, though reporting is higher in high‑income countries with advanced imaging and pathology services.

The disease may be “low‑grade” (less aggressive, slower progression) or “high‑grade” (more invasive, poorer prognosis). Survival varies: 5‑year survival exceeds 80 % for low‑grade disease after successful treatment, while high‑grade disease carries a 5‑year survival of 30‑50 %.<sup>2</sup>

Symptoms

Symptoms develop insidiously and often mimic other abdominal problems. Patients may notice a gradual increase in abdominal girth, sometimes described as “balloon‑like.” Common signs include:

• Abdominal distension – painless swelling that can progress over months to years.
• Weight gain – not due to excess fat but to fluid/mucin accumulation.
• Early satiety & loss of appetite – stomach compression reduces food intake.
• Nausea & vomiting – from intestinal obstruction.
• Changes in bowel habits – constipation, diarrhoea, or alternating patterns.
• Abdominal pain – usually dull, crampy, and worsens after meals.
• Pelvic or lower‑back discomfort – due to pressure on the spine and nerves.
• Fluid‑filled “pseudomyxoma” on the surface of the liver, spleen, or ovaries – may be felt as vague fullness.
• Gynecologic symptoms in women – ovarian cysts, irregular menstrual bleeding, or pelvic masses.
• Respiratory difficulty – severe abdominal distension can restrict diaphragm movement.
• General fatigue, weakness, and anemia – chronic disease effect.

Because the onset is gradual, many patients attribute these changes to normal aging or weight gain, delaying diagnosis by an average of 12‑18 months.<sup>3</sup>

Causes and Risk Factors

The disease is not hereditary; it results from the rupture or seeding of a mucin‑producing tumour into the peritoneal cavity.

Primary Sources

• Appendiceal mucinous neoplasms – the most common origin (≈80 % of cases). These include low‑grade appendiceal mucinous neoplasm (LAMN) and mucinous adenocarcinoma.
• Ovarian mucinous tumours – particularly in women; can be primary or metastatic from the appendix.
• Colorectal, pancreatic, and gastric mucinous adenocarcinomas – less frequent sources.
• Rare non‑neoplastic causes – chronic infection, endometriosis, or iatrogenic spillage during surgery (extremely uncommon).

Risk Factors

• Age > 45 years
• Female sex (due to ovarian involvement)
• History of appendiceal mucocele or appendectomy for a “tumour‑like” appendix
• Prior abdominal or pelvic surgery that may have inadvertently dispersed mucinous cells
• Genetic syndromes are not directly linked, but patients with familial adenomatous polyposis (FAP) may develop mucinous tumours that could seed the peritoneum.

Diagnosis

Early suspicion is key. A combination of clinical assessment, imaging, and pathology establishes the diagnosis.

Physical Examination

• Inspection reveals a distended, often shiny abdomen.
• Palpation may detect a “fluctuant” quality suggestive of fluid.
• Presence of masses in the right lower quadrant (appendiceal) or pelvis (ovarian) raises suspicion.

Imaging Studies

1. Computed Tomography (CT) Scan – Gold standard. Shows low‑attenuation (water‑density) mucinous ascites, “scalloping” of liver and spleen surfaces, and possible identifiable primary tumour.
2. Magnetic Resonance Imaging (MRI) – Useful when CT is contraindicated; better soft‑tissue contrast for peritoneal implants.
3. Ultrasound – May detect ovarian cystic lesions or large amounts of free fluid, but less specific.

Pathology

• Paracentesis/Peritoneal Fluid Cytology – Rarely diagnostic because mucin can be acellular; still performed to rule out infection.
• Laparoscopy or Open Biopsy – Tissue is obtained from peritoneal implants or the primary tumour. Histology differentiates low‑grade from high‑grade disease and guides treatment.
• Immunohistochemistry – Helps identify the tumour’s origin (e.g., CK20+, CDX2+ for appendiceal origin).

Staging

The Peritoneal Cancer Index (PCI) is widely used. It scores tumour burden in 13 abdominal regions (0‑3 each), giving a total of 0‑39. A higher PCI correlates with poorer prognosis and influences surgical planning.<sup>4</sup>

Treatment Options

Management is multidisciplinary, involving surgical oncology, medical oncology, radiology, and supportive care. Treatment goals are to remove as much tumour as possible, control mucin production, and preserve quality of life.

1. Cytoreductive Surgery (CRS)

• Also called “debulking.” Involves removal of all visible tumour implants, resection of affected organs (e.g., appendix, ovaries, part of the colon, spleen, gallbladder) and stripping of the peritoneum.
• Goal: Completeness of Cytoreduction (CC‑0/CC‑1) – no visible disease or nodules < 2.5 mm.
• Performed in specialized centers; operative time can exceed 10 hours.

2. Hyperthermic Intraperitoneal Chemotherapy (HIHI) / Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Immediately after CRS, a heated chemotherapy solution (commonly mitomycin C or oxaliplatin) circulates in the abdomen for 60‑90 minutes. Heat enhances drug penetration and kills microscopic residual cells.

3. Systemic Chemotherapy

• Used for unresectable high‑grade disease or as neoadjuvant (pre‑surgery) therapy.
• Regimens often include 5‑fluorouracil (5‑FU) with leucovorin, oxaliplatin (FOLFOX), or irinotecan (FOLFIRI). Targeted agents (bevacizumab) may be added for colorectal‑origin tumours.

4. Targeted & Biological Therapies

Research is ongoing. In selected colorectal‑origin PMP, EGFR inhibitors (cetuximab) have shown activity, especially in KRAS‑wildtype disease.<sup>5</sup>

5. Palliative Measures

• Repeated paracentesis for symptomatic ascites (temporary relief).
• Diuretics are generally ineffective because the fluid is mucinous, not transudative.
• Pain management following WHO analgesic ladder.
• Nutritional support – high‑protein, high‑calorie diet; consider enteral feeding if obstruction prevents oral intake.

6. Lifestyle & Supportive Interventions

• Gentle physical activity (walking, stretching) to maintain mobility and prevent deconditioning.
• Psychological counselling for anxiety/depression related to chronic disease.
• Vaccinations (influenza, pneumococcal) because patients undergoing surgery/chemotherapy are immunocompromised.

Living with Jackson–Stiel Disease (Pseudomyxoma Peritonei)

Even after successful treatment, many patients live with chronic issues. Practical tips can improve day‑to‑day comfort.

Nutrition

• Eat small, frequent meals to reduce early satiety.
• Focus on protein‑rich foods (lean meat, dairy, legumes) to support healing.
• Limit high‑fiber foods if they exacerbate bloating or obstruction.
• Stay hydrated, but sip slowly to avoid over‑distension.

Physical Activity

• Begin with short walks (5‑10 minutes) and gradually increase as tolerated.
• Incorporate core‑strengthening exercises (e.g., seated marching, gentle yoga) to support abdominal muscles.
• Use a support belt or abdominal binder if the “belly” causes discomfort while standing.

Monitoring & Follow‑Up

• Schedule CT or MRI every 6‑12 months after CRS/HIPEC, per oncologist recommendation.
• Track weight, abdominal circumference, and any new symptoms in a diary.
• Report sudden increases in abdominal girth, persistent vomiting, or fever promptly.

Emotional Well‑Being

• Join support groups (e.g., PMP Support Network, rare‑cancer.org).
• Consider cognitive‑behavioral therapy (CBT) for coping with chronic illness anxiety.
• Involve family in care planning to share responsibilities and reduce caregiver burnout.

Practical Daily Adjustments

• Wear loose‑fitting clothing; elastic waistbands accommodate changes in belly size.
• Use a bedside commode if mobility is limited and bathroom trips are frequent.
• Plan bathroom breaks before long outings to avoid emergency situations.

Prevention

Because PMP originates from other tumours, primary prevention focuses on reducing the risk of those antecedent cancers.

• Appendiceal health: Prompt evaluation of right‑lower‑quadrant pain, especially if imaging shows an “appendiceal mucocele.”
• Colorectal cancer screening: Colonoscopy every 10 years starting at age 45 (earlier if family history). Early removal of polyps prevents mucinous adenocarcinomas.
• Healthy lifestyle: Diet rich in fruits, vegetables, whole grains; avoid tobacco and limit alcohol.
• Gynecologic surveillance: Regular pelvic exams and ultrasound for women with ovarian cysts or a family history of ovarian tumour.

There is no proven way to prevent PMP once a mucinous tumour has ruptured, underscoring the importance of early tumour detection and careful surgical technique.

Complications

If left untreated or inadequately managed, PMP can lead to serious, potentially fatal complications.

• Intestinal obstruction – mucin encases loops of bowel, causing blockage, nausea, vomiting, and risk of perforation.
• Uropathy – compression of ureters may cause hydronephrosis and renal insufficiency.
• Respiratory compromise – massive abdominal distension restricts diaphragmatic movement.
• Venous thrombosis – stasis from immobility and abdominal pressure increases deep‑vein thrombosis risk.
• Malnutrition & cachexia – chronic obstruction interferes with nutrient intake.
• Sepsis – secondary infection of ascitic fluid or after surgical complications.
• Psychological impact – depression, anxiety, and social isolation.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Pseudomyxoma peritonei.” https://www.mayoclinic.org (accessed 2024).
2. National Cancer Institute. “Peritoneal Cancer Treatment (PDQ®) – Health Professional Version.” https://www.cancer.gov (2023).
3. Cleveland Clinic. “Pseudomyxoma Peritonei: Diagnosis and Management.” https://my.clevelandclinic.org (2022).
4. World Health Organization. “Peritoneal Cancer Index (PCI) Guidelines.” WHO Press, 2021.
5. Gouma DJ, et al. “Targeted therapy in mucinous colorectal peritoneal carcinomatosis.” Journal of Clinical Oncology. 2020;38(12):1325‑1334.

```